BUPIDRIVE Injection

BUPIDRIVE Injection is a Bupivacaine Hydrochloride formulation intended for local and regional anaesthesia in appropriate clinical settings. Bupivacaine is a long-acting amide-type local anaesthetic that produces reversible loss of sensation by inhibiting the generation and conduction of nerve impulses at the site of administration.

The injectable is used by qualified healthcare professionals for regional anaesthetic techniques where prolonged local or regional anaesthesia is clinically required. Its pharmacological profile makes it relevant to a range of surgical and procedural applications in which effective sensory blockade is required.

BUPIDRIVE Injection is presented in a convenient 4 mL ampoule format and supplied as a pack of 5 ampoules. The product is intended for professional administration using an appropriate anaesthetic technique and route selected according to the procedure, patient condition and clinical requirement.

Bupivacaine is commonly used in regional anaesthesia, including selected peripheral nerve blocks, local infiltration and other established regional anaesthetic procedures. Its relatively long duration of action can provide sustained anaesthesia for suitable surgical and procedural interventions.

For pharmaceutical distributors, hospital procurement teams and institutional healthcare suppliers, BUPIDRIVE Injection adds a specialized local anaesthetic to the injectable portfolio. It may be relevant to hospitals, surgical departments, operating theatres, anaesthesia departments and other healthcare facilities where regional anaesthetic medicines are routinely required.

The product should be administered only by appropriately trained healthcare professionals. Proper dose selection, injection technique and patient monitoring are important because accidental intravascular administration or excessive systemic exposure to bupivacaine can result in serious adverse effects. Use should therefore follow approved prescribing information and established clinical protocols.